Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lianhua Yuping (specifically developed as Lianhua Yuping Granules) is an innovative traditional Chinese medicine (TCM) formulation developed by Yiling Pharmaceutical. It is formulated based on the collateral disease theory (络病理论) and is derived from a combination of three classic TCM formulas: Yuping Feng San (玉屏风散), Guizhi Decoction (桂枝汤), and Yinqiao Powder (银翘散). The formulation is designed to treat the common cold with qi deficiency syndrome (感冒气虚证) by replenishing qi, consolidating the defensive exterior (益气固卫), expelling wind, and resolving toxins (祛风解毒). It is currently in Phase II clinical development in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lianhua Yuping.
Work on Lianhua Yuping? Claim this page to correct or add information. Claim this page